Free Newsletter
U.S. Attys probe Schering over Vytorin
The ranks of investigators probing Schering-Plough and its Vytorin drug are broadening. In a recent SEC filing, Schering disclosed that U.S. Attorneys have been asking for info and documents related to the controversial Enhance trial, which pitted the combo cholesterol drug Vytorin against partner Merck's statin drug Zocor.
That trial, as you know, has been under scrutiny for months now as Merck/Schering-Plough dragged its feet in releasing the results, considering changing its primary endpoint, and then finally reported that Vytorin performed no better than Zocor alone at treating arterial clogging (though it did a better job of lowering bad cholesterol).
Details of the U.S. Attorneys' probes are scant; at this point, all we know is that another government official (or two or more, we don't know how many) has joined the investigatory fray. It's already well crowded with Senators, Congressional committees, state attorneys general and the like. We'll keep you posted.
- see the Pharmalot item
- check out the Shearlings Got Plowed dissection of the 10-Q filing
- read the filing itself at the SEC website
Related Articles:
Fissures in Merck, Schering relationship?
A turbulent week for Fred Hassan
Schering-Plough laying off 5,500
Congress: M/S-P sat on bad news
Congress: Were Enhance results secret?
Comments
By condor | Posted 6:30pm | May 7, 2008
Actually we do know a LITTLE more about the US Attorneys' investigation -- and Pharmalot links to mine, for that part of the story, but here it is -- pretty fascinating internet age sleuthing is suddenly at the fore, here:
www [dot] shearlingsplowed [dot]
blogspot [dot] com/2008/04/very-interesting-visitor-path-evening [dot] html
[Just replace each [dot] with a period -- . -- above.]
Thanks for the mention on the Form 10-Q dissection, as well.
-- condor
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: